Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
At $31 a day, is Vertex’s new non-addictive painkiller worth the price?
Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Vertex: YOY Decline In Q4 Earnings Expected, But Revenue Continues To Shine
Vertex to see decline in earnings but double-digit revenue growth with new drug JOURNAVX and CF franchise expansion, positioning for long-term growth.
Vertex Pharmaceuticals Stock Jumps After FDA Approval for New Non-Opioid Painkiller
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
Wall Street Journal1d
Vertex Pharmaceuticals Inc.
1 Day VRTX -0.71% DJIA 0.38% S&P 500 0.53% Health Care/Life Sciences 0.19% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...